ATE289816T1 - Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen - Google Patents

Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen

Info

Publication number
ATE289816T1
ATE289816T1 AT98962348T AT98962348T ATE289816T1 AT E289816 T1 ATE289816 T1 AT E289816T1 AT 98962348 T AT98962348 T AT 98962348T AT 98962348 T AT98962348 T AT 98962348T AT E289816 T1 ATE289816 T1 AT E289816T1
Authority
AT
Austria
Prior art keywords
mirtazapine
medication
treatment
production
sleep apnoea
Prior art date
Application number
AT98962348T
Other languages
English (en)
Inventor
John Stuart Andrews
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of ATE289816T1 publication Critical patent/ATE289816T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98962348T 1997-11-14 1998-11-13 Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen ATE289816T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97203548 1997-11-14
PCT/EP1998/007330 WO1999025356A1 (en) 1997-11-14 1998-11-13 Use of mirtazapine for treating sleep apneas

Publications (1)

Publication Number Publication Date
ATE289816T1 true ATE289816T1 (de) 2005-03-15

Family

ID=8228923

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962348T ATE289816T1 (de) 1997-11-14 1998-11-13 Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen

Country Status (20)

Country Link
US (1) US6303595B1 (de)
EP (1) EP1030667B1 (de)
JP (1) JP2001522891A (de)
KR (1) KR20010032009A (de)
CN (1) CN1154495C (de)
AT (1) ATE289816T1 (de)
AU (1) AU737590B2 (de)
BR (1) BR9815098A (de)
CA (1) CA2309744A1 (de)
CZ (1) CZ296282B6 (de)
DE (1) DE69829202T2 (de)
DK (1) DK1030667T3 (de)
ES (1) ES2238781T3 (de)
HU (1) HUP0100080A3 (de)
IL (2) IL135825A0 (de)
NO (1) NO20002218L (de)
PL (1) PL192272B1 (de)
PT (1) PT1030667E (de)
TR (1) TR200001293T2 (de)
WO (1) WO1999025356A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060241164A1 (en) * 1998-02-27 2006-10-26 The Board Of Trustees Of The University Of Illinoi Pharmacological treatment for sleep apnea
WO1999043319A1 (en) 1998-02-27 1999-09-02 The Board Of Trustees Of The University Of Illinois Agents with serotonin-related activity for the treatment for sleep apnea
US7160898B2 (en) 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
ES2258071T3 (es) * 2000-02-11 2006-08-16 Akzo Nobel N.V. Utilizacion de mirtazepina para trastornos del sueño.
US20020183306A1 (en) * 2001-05-30 2002-12-05 Pfizer Inc. Combination treatment for sleep disorders including sleep apnea
UA83666C2 (ru) 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
EP1667972B1 (de) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomere von 4-aryloxy-3-hydroxypiperidinen
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
EP1827450A4 (de) * 2004-11-17 2009-04-22 Cypress Bioscience Inc Verfahren zur verringerung der nebenwirkungen einer behandlung mit mirtazapin
AU2005319367B2 (en) * 2004-12-20 2012-05-24 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
JP5635905B2 (ja) 2007-04-11 2014-12-03 メルク・シャープ・エンド・ドーム・ベー・フェー ミルタザピンの調製方法
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
US10172920B2 (en) 2012-06-14 2019-01-08 The Regents Of The University Of Michigan Sleep apnea treatment
SI3261645T1 (sl) 2015-02-27 2021-08-31 Dechra Limited Stimulacija apetita, uravnavanje izgube mase in zdravljenje anoreksije pri psih in mačkah

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
EP0517984A1 (de) * 1991-06-11 1992-12-16 Merrell Dow Pharmaceuticals Inc. Amidanaloge-Derivate von methanoverbrückten Chinolizinen
JPH11515015A (ja) * 1995-10-24 1999-12-21 グルーエネンタール ゲゼルシャフト ミット ベシュレンクテル ハフツング 睡眠無呼吸の抑止方法
SE9504537D0 (sv) 1995-12-19 1995-12-19 Jan Hedner Sätt att behandla och diagnosticera andningsstörningar under sömn och medel för utförande av sättet
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent

Also Published As

Publication number Publication date
WO1999025356A1 (en) 1999-05-27
CZ20001751A3 (cs) 2000-10-11
HUP0100080A3 (en) 2002-05-28
DE69829202T2 (de) 2005-07-21
DK1030667T3 (da) 2005-06-20
IL135825A (en) 2006-12-31
PL192272B1 (pl) 2006-09-29
CA2309744A1 (en) 1999-05-27
CN1278731A (zh) 2001-01-03
KR20010032009A (ko) 2001-04-16
CZ296282B6 (cs) 2006-02-15
US6303595B1 (en) 2001-10-16
AU737590B2 (en) 2001-08-23
HUP0100080A2 (hu) 2001-08-28
HK1029932A1 (en) 2001-04-20
ES2238781T3 (es) 2005-09-01
TR200001293T2 (tr) 2002-09-23
EP1030667B1 (de) 2005-03-02
CN1154495C (zh) 2004-06-23
PT1030667E (pt) 2005-06-30
PL340467A1 (en) 2001-02-12
JP2001522891A (ja) 2001-11-20
BR9815098A (pt) 2000-10-10
AU1754899A (en) 1999-06-07
DE69829202D1 (de) 2005-04-07
EP1030667A1 (de) 2000-08-30
IL135825A0 (en) 2001-05-20
NO20002218L (no) 2000-05-12
NO20002218D0 (no) 2000-04-28

Similar Documents

Publication Publication Date Title
ATE289816T1 (de) Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
ATE373474T1 (de) Substituierte 2-aminotetraline zur behandlung von depressionen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE415962T1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
ATE307203T1 (de) Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE69227583D1 (de) Arylmorpholine, herstellung und verwendung
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69627298D1 (de) Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten
ATE239492T1 (de) Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen
DE60024408D1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
DE60313344D1 (de) Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
ATE345124T1 (de) Verwendung von l-acetylcarnitin zur herstellung eines medikaments zur behandlung von anhedonia
ATE330597T1 (de) Verwendung von fibrate zur herstellung eines arzneimittel zur behandlung von kongestiven herzversagens
DE50105253D1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus
DE60128130D1 (de) Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a
ATE308321T1 (de) Verwendung von c2-substituierten indan-1-ol- systemen zur herstellung von medikamenten zur prophylaxe oder behandlung von obesitas

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1030667

Country of ref document: EP

REN Ceased due to non-payment of the annual fee